Silencing of

Ewelina Jozefczuk, Piotr Szczepaniak, Tomasz Jan Guzik, Mateusz Siedlinski

Open access · goldAbstract read

In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 48% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

Sphingosine-1-phosphate activates IJournal of molecular and cellular cardiology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Ewelina JozefczukDepartment of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Cracow, Poland.

Piotr SzczepaniakDepartment of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Cracow, Poland.

Tomasz Jan GuzikDepartment of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Cracow, Poland.

Mateusz SiedlinskiDepartment of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Cracow, Poland.

Jagiellonian University · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego N41/DBS/000115Ministerstwo Nauki i Szkolnictwa Wyższego N41/DBS/000243Narodowe Centrum Nauki 2016/22/E/NZ4/00610

6 · The paper itself

Abstract

Sphingosine kinase-1 (Sphk1) and its product, sphingosine-1-phosphate (S1P) are important regulators of cardiac growth and function. Numerous studies have reported that Sphk1/S1P signaling is essential for embryonic cardiac development and promotes pathological cardiac hypertrophy in adulthood. However, no studies have addressed the role of Sphk1 in postnatal cardiomyocyte (CM) development so far. The present study aimed to assess the molecular mechanism(s) by which

Indexed as

AnimalsAnimals, NewbornCell DifferentiationCell ProliferationLysophospholipidsMiceMice, Inbred C57BLMyocytes, CardiacPhosphotransferases (Alcohol Group Acceptor)Receptors, LysosphingolipidRNA, Small InterferingSignal TransductionSphingosineSphingosine KinaseLysophospholipidsPhosphotransferases (Alcohol Group Acceptor)Receptors, LysosphingolipidRNA, Small InterferingSphingosinesphingosine 1-phosphateSphingosine KinaseSphk1 protein, mousecardiomyocytecardiomyocyte hypertrophycardiomyocyte maturationcardiomyocyte proliferationsphingosine-1-phosphatesphingosine kinase-1

Identifiers

PMID33807180

DOI10.3390/ijms22073616

PMCPMC8037404

OpenAlexW3140739810

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.